Exome Asset Management LLC Sells 659,200 Shares of Gossamer Bio, Inc. (NASDAQ:GOSS)

Exome Asset Management LLC trimmed its holdings in shares of Gossamer Bio, Inc. (NASDAQ:GOSS) by 58.5% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 468,499 shares of the company’s stock after selling 659,200 shares during the quarter. Exome Asset Management LLC owned about 0.21% of Gossamer Bio worth $462,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. Marshall Wace LLP increased its holdings in shares of Gossamer Bio by 170.8% during the second quarter. Marshall Wace LLP now owns 3,335,511 shares of the company’s stock worth $3,002,000 after purchasing an additional 2,103,766 shares during the period. NEA Management Company LLC raised its holdings in Gossamer Bio by 14.2% in the 2nd quarter. NEA Management Company LLC now owns 18,093,034 shares of the company’s stock valued at $16,300,000 after acquiring an additional 2,255,025 shares in the last quarter. GSA Capital Partners LLP acquired a new stake in shares of Gossamer Bio during the 3rd quarter worth $67,000. Acadian Asset Management LLC increased its position in shares of Gossamer Bio by 31.3% in the second quarter. Acadian Asset Management LLC now owns 3,592,765 shares of the company’s stock worth $3,235,000 after purchasing an additional 856,380 shares during the period. Finally, Monaco Asset Management SAM raised its stake in Gossamer Bio by 390.3% in the second quarter. Monaco Asset Management SAM now owns 2,726,104 shares of the company’s stock valued at $2,456,000 after purchasing an additional 2,170,104 shares in the last quarter. Institutional investors and hedge funds own 81.23% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Gossamer Bio in a research note on Monday, November 11th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $9.20.

Gossamer Bio Stock Performance

NASDAQ:GOSS opened at $0.93 on Friday. The stock’s 50-day moving average is $0.84 and its 200-day moving average is $0.87. Gossamer Bio, Inc. has a 1-year low of $0.50 and a 1-year high of $1.60. The company has a current ratio of 6.74, a quick ratio of 6.74 and a debt-to-equity ratio of 3.64. The stock has a market cap of $210.74 million, a P/E ratio of -2.91 and a beta of 1.85.

Gossamer Bio (NASDAQ:GOSS) last posted its earnings results on Thursday, November 7th. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.04. The business had revenue of $9.48 million for the quarter, compared to the consensus estimate of $4.52 million. Equities research analysts anticipate that Gossamer Bio, Inc. will post -0.28 earnings per share for the current year.

Gossamer Bio Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.